Skip to main content
Premium Trial:

Request an Annual Quote

Caprion and Ecopia Raise $45M in Merger Financing

NEW YORK (GenomeWeb News) — Ecopia BioSciences and Caprion Pharmaceuticals today said they received $45 million in a private placement tied to their merger.
The firms had said they expected to raise between $30 million and $45 million in the placement, which is being handled by the securities companies Desjardins and Dundee.  
The companies said they will use the funding for drug development after they complete their merger to form a new company to be called Thallion Pharmaceuticals. The firms had planned to call the new company Amalco.
As GenomeWeb News reported in January, the companies said they plan to divest Caprion’s CellCarta proteomics unit in 2007, which would leave Thallion to focus on oncology and infectious disease therapeutics.
Caprion President and CEO Lloyd Segal will serve as CEO of the new company.
Ecopia President and CEO Pierre Falardeau said the funds from the offering will “allow Thallion to drive the development of all thee of its clinical products.”

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.